Methylphenidate

RITALIN

Open Methylphenidate in the interactive console ↗

Pronunciation: meth-il-FEN-i-dayt (RIT-a-lin)

Methylphenidate ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Methylphenidate ballicule

Methylphenidate RITALIN mascot mnemonic cartoon — Visual mnemonic: Methylphenidate mascot
**“Write a line on Math final date”**
Wide eyes → symbol for stimulant

What it isDopamine and norepinephrine reuptake inhibitor; ADHD and narcolepsy.

Why this oneIts exceptional formulation range includes short-acting, osmotic-release, liquid, chewable, patch, and bedtime-dosed products.

What limits itAppetite loss, insomnia, and slowed growth can end treatment; monitor blood pressure, heart rate, and misuse.

Methylphenidate molecular structure (skeletal formula) — Molecular structure: Methylphenidate

FDA-approved for

ADHD (1955)
narcolepsy (~1960)

Off-label

treatment-resistant depression augmentation

FDA label

Read the full label on DailyMed ↗

BOXED WARNING High potential for abuse and misuse → substance use disorder incl. addiction; CNS-stimulant misuse/abuse can cause overdose and death (risk higher with high doses or snorting/injection). Assess abuse risk before prescribing; monitor throughout treatment.

FDA dosing	Population	Start	Target	Max
ADHD; narcolepsy (general dosing)	Peds ≥6 yr	5 mg BID (before breakfast & lunch)	Individualized; ↑5–10 mg weekly	60 mg/day (above not recommended)
ADHD; narcolepsy (general dosing)	Adults	20–30 mg/day in 2–3 divided doses, 30–45 min before meals	20–30 mg/day average	60 mg/day

Titration Peds: increase weekly (5–10 mg increments)

Renal Undefined

Hepatic Undefined

Instructions

Take 30–45 min before meals (adults); peds doses before breakfast and lunch
If insomnia, take last dose before 6 p.m.
Reduce dose or discontinue if paradoxical worsening or adverse reactions
Discontinue if no improvement after appropriate dose adjustment over 1 month
Pretreatment: cardiac history/exam and screen for tics/Tourette's and family history

Available strengths

tab 5, 10, 20 mg
cap 20, 40, 60, 80, 100 mg
ER cap 10, 15, 20, 30, 40, 50, 60, 80, 100 mg
ER tab 10, 18, 20, 27, 36, 45, 54, 63, 72 mg
ODT 8.6, 17.3, 25.9 mg
chew tab 2.5, 5, 10, 20, 30, 40 mg
ER susp 600 mg/120 mL
ER susp 750 mg/150 mL
+ 5 other marketed forms not shown

Contraindications

Concomitant MAOI treatment, or within 14 days of stopping an MAOI (hypertensive crisis risk)

Cautions

Avoid in serious cardiac disease (structural abnormality, cardiomyopathy, serious arrhythmia, CAD)
Increases BP and heart rate — monitor
Psychiatric adverse reactions: screen for mania risk; consider discontinuing if new psychosis/mania
Priapism — immediate medical attention if sustained/frequent painful erections
Peripheral vasculopathy incl. Raynaud's — observe digits
Long-term growth suppression in peds — monitor height/weight; interrupt treatment if not growing as expected
Acute angle-closure glaucoma risk; caution with increased IOP/open-angle glaucoma
Emergence/worsening of motor and verbal tics and Tourette's — monitor

Adverse reactions

Common: tachycardia, palpitations, headache, insomnia, anxiety, hyperhidrosis, weight loss, decreased appetite, dry mouth, nausea, abdominal pain
Also: psychosis/hallucinations, growth suppression (peds), blurred vision, dyskinesia, seizures, hepatic injury, Raynaud's, rash/urticaria, leukopenia/thrombocytopenia, priapism

Pregnancy Published data have not identified drug-associated risk of major birth defects/miscarriage; possible CNS-stimulant fetal risks; pregnancy exposure registry available

Lactation Present in milk (infant dose 0.16–0.7% of maternal weight-adjusted dose); no adverse infant reports; monitor infant for agitation, insomnia, anorexia, reduced weight gain

Cost

Methylphenidate (RITALIN)

What pharmacies pay · NADAC 9/30/26

Strength		#/mo	generic $/unit	CostPlus
5 mg	tab	per unit	$0.13/ea	not offered
10 mg	tab	per unit	$0.16/ea	not offered
20 mg	tab	per unit	$0.20/ea	not offered

Other forms: Methylphenidate ER chewable (QUILLICHEW ER) · Methylphenidate ER suspension (QUILLIVANT XR) · Methylphenidate ER (Relexxii) · Methylphenidate LA (RITALIN LA) · Methylphenidate ER (OROS) (CONCERTA) · Methylphenidate XR-ODT (COTEMPLA XR-ODT) · Methylphenidate patch (DAYTRANA) · Methylphenidate ER evening-dosed (JORNAY PM) · Methylphenidate CD (METADATE CD) · Methylphenidate oral solution (METHYLIN SOLUTION)

Generic entry2020

⚠ BOXED WARNING

Abuse, misuse and addiction

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4

Overdose danger3 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityHypertension, appetite/weight effects, misuse and stimulant-induced psychosis or arrhythmia.

Serotonicity

This drug is routinely called serotonergic. By Gillman’s human-effect criteria it does not raise serotonin in the synapse.

No clinically meaningful serotonin-elevating mechanism identified in this first-pass Gillman-based review.

Label contraindicationConcomitant MAOI treatment, or within 14 days of stopping an MAOI (hypertensive crisis risk). The label governs prescribing; Gillman’s point concerns serotonin toxicity only.

Gillman’s four human testsA measurable SERT affinity that fails all four is not clinical serotonicity.